Form 4: Bristol-Myers Squibb Executive Acquires Market Share and Performance Units

Benjamin Hickey, President of RayzeBio Org., reports acquisition of market share and performance units in Bristol-Myers Squibb, according to a Form 4 filing.

Summary

• Benjamin Hickey, President of RayzeBio Org., filed a Form 4 disclosing changes in beneficial ownership of Bristol-Myers Squibb (BMY) securities.
• The reported transactions include the acquisition of 13,389 market share units and 20,084 performance shares on March 10, 2025.
• These derivative securities are linked to Bristol-Myers Squibb common stock and are subject to performance-based vesting conditions.
• Hickey also directly owns 8,789 shares of BMY common stock and indirectly owns 91 shares through a spouse.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing reflecting executive compensation. The positive aspect is the alignment of executive interests with company performance, but there are inherent risks associated with performance-based compensation.

Positives

• The acquisition of market share and performance units aligns Hickey's interests with the long-term performance of Bristol-Myers Squibb.
• The performance-based vesting conditions incentivize Hickey to drive shareholder value.

Risks

• The value of the market share units and performance shares is contingent on Bristol-Myers Squibb's future performance and Board certification of results.
• The payout factor for market share units is subject to a minimum and maximum, potentially limiting the upside.

Future Outlook

The value of the acquired market share units and performance shares depends on Bristol-Myers Squibb's future stock performance and achievement of performance targets.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. This filing indicates that a key executive is incentivized to improve the company's performance.

Comparison to Industry Standards

• Performance-based equity compensation is a common practice among publicly traded companies to align executive compensation with shareholder value creation.
• The specific terms of the market share units and performance shares, such as the payout factor and performance metrics, are tailored to Bristol-Myers Squibb's business strategy and industry dynamics.
• Similar compensation structures can be found at peer companies like Johnson & Johnson (JNJ) and Merck & Co. (MRK), where executive compensation is tied to financial performance and shareholder returns.

Stakeholder Impact

• Shareholders: The acquisition of performance-based equity aligns executive incentives with shareholder value creation.
• Employees: The filing provides transparency into executive compensation practices.
• Executive: The executive is incentivized to improve company performance.

Key Dates